Relapsed and/or Refractory Multiple Myeloma Clinical Trial
Official title:
Phase 2a Single-Arm Safety Study of Elotuzumab in Combination With Thalidomide and Dexamethasone in Subjects With Relapsed and/or Refractory Multiple Myeloma
The purpose of this study is to determine the safety and tolerability of elotuzumab administered in combination with thalidomide and dexamethasone in the treatment of relapsed and/or refractory multiple myeloma.
n/a
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03140943 -
Carfilzomib Thalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
|
Phase 2 | |
| Recruiting |
NCT05066022 -
A Study to Access the Safety and Efficacy of CT0590 in Patients With Relapsed and/or Refractory Multiple Myeloma
|
N/A | |
| Recruiting |
NCT06182696 -
OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03715478 -
Multi-Center Study of GSK2857916 in Combination With Pomalidomide and Dex
|
Phase 1/Phase 2 | |
| Completed |
NCT02917941 -
A Study of Ixazomib Plus Lenalidomide and Dexamethasone in Adult Japanese Participants With Relapsed and/or Refractory Multiple Myeloma
|
Phase 2 | |
| Not yet recruiting |
NCT03903406 -
Quality of Life, Symptoms and Treatment Satisfaction in Adult Patients With Relapsed and/or Refractory Multiple Myeloma, Receiving Ixazomib (Ninlaro®) in Combination With Lenalidomide and Dexamethasone in a Real World Setting: Pilot Study
|
||
| Completed |
NCT03242460 -
The Safety and Efficacy of Pomalidomide in Combination With Cyclophosphamide and Dexamethasone (PCD) in the Transplant-ineligible Patients With Relapsed and/or Refractory Multiple Myeloma (MM)
|
Phase 2 | |
| Terminated |
NCT03836053 -
Assessment of AMG 420 in Subjects With Relapsed and/or Refractory Multiple Myeloma
|
Phase 1 | |
| Recruiting |
NCT05719701 -
Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients With Relapsed and/or Refractory Multiple Myeloma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05297240 -
Retrospective Study of the Use of Belantamab Mafodotin (Blenrep®) in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) in Spain.
|
||
| Terminated |
NCT04272775 -
A Study of MLN9708 in Japanese Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM)
|
Phase 1 | |
| Not yet recruiting |
NCT06351644 -
ON 123300 (Narazaciclib) and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT04392648 -
A Study to Evaluate the Safety, Tolerability and Efficacy of Intravenous TAK-573 as Part of Combination Therapy in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
|
Phase 1 | |
| Completed |
NCT02831686 -
A Study to Test the Combination of Selinexor (KPT-330), Ixazomib, and Dexamethasone in Patients With Myeloma
|
Phase 1 | |
| Recruiting |
NCT06153251 -
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
|
Phase 1 | |
| Completed |
NCT00882063 -
Study To Evaluate Safety and Efficacy of P276-00 in Subjects With Refractory Multiple Myeloma
|
Phase 1/Phase 2 | |
| Terminated |
NCT04017130 -
A Study of MT-0169 in Participants With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
| Completed |
NCT03416374 -
A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy
|
Phase 4 | |
| Recruiting |
NCT05486975 -
This is an Open-label, Single Arm Study to Evaluate the Safety and Tolerability of Treatment With CT0591CP in Patients With Relapsed and/or Refractory Multiple Myeloma.
|
Early Phase 1 | |
| Completed |
NCT03170882 -
A Study of Ixazomib, Given With Dexamethasone in Adults With Multiple Myeloma
|
Phase 2 |